A filing is not a verdict. Nothing on this site is a finding of liability.
The Record — theasbaghirecord.com. A filing is not a verdict. Nothing on this site is a finding of liability.
Section 04b
California Court of Appeal, Fourth Appellate District, Division One. Mara Gerloni v. Maurizio Zanetti, D059695, Superior Court GIC868327. Filed 1 February 2013. Unpublished under California Rules of Court, rule 8.1115. Short holding as printed: derivative, no standing as a non-shareholder; contract and fraud counts failed on deposition. The same opinion recites the Transgenix / Cosmo Bioscience sale and that in 2005 Gerloni left UCSD to become CBI’s chief executive officer. Eighteen calendar days after the alleged 14 January 2013 Padtan meeting is a calendar fact. Coordinated use of this lawsuit as a twenty-year shield remains his claim. Nature, 13 February 1997, is contemporaneous reporting, not a retry.
On the documents
Documented. Zanetti was a UCSD professor of medicine. Gerloni joined that lab as a postdoctoral fellow in 1993. Transgenics was a real company. Cosmo later bought that vehicle and renamed it Cosmo Bioscience. The unpublished 2013 opinion recites that sale ($18,000 to Zanetti) and the 2005 CEO appointment. A ResearchGate snippet still prints CEO at Cosmo Bioscience. An image result captions Cosmo Pharmaceuticals NV — a related public name, not proof the two Cosmo vehicles are one filing. A Cosmo 10-K note describes Cosmo Bioscience v. Adamis and Zanetti, filed May 2010. Nature, 13 February 1997, reported a UCSD misconduct charge that included human-experiment and biosafety-policy allegations; a later faculty panel recommended a reprimand for guideline violations while rejecting fabrication; the 2013 opinion recites a tenure-committee exoneration. A federal court rejected Gerloni’s co-inventor claim. This page is the state appeal. The 20-page opinion is not reprinted here. The contemporary news item is Rex Dalton, “Heat rises over UCSD ‘misconduct’ charge,” Nature.
Claimed. Ommid working in that lab, dating Zanetti, and introducing Ghasemi for Iranian trials remains his account until a personnel page, grant, or contemporaneous letter is mounted. Trans In’Tech, LLC is a real California entity whose public officers include names from this family; “cover-up company” is the allegation, not the filing. Coordinated use of Gerloni v. Zanetti as a twenty-year shield for Padtan Elm or Iranome remains claimed. Unconsented human trials stay alleged in that 1997 reporting, not a verdict on this page.
Documented · as the unpublished opinion recites it
The copy of D059695 is the original for this section. The appellate court did not retry inventorship. It affirmed summary judgment because Gerloni’s own deposition did not raise a triable issue on the contract and fraud counts that survived as individual claims.
The opinion recites a first deposition on 8 September 2006 — just over a month after she signed a declaration describing promises. At deposition she did not recall Dr. Zanetti telling her she would be a director of Transgenics, whether she attended any directors’ meeting, or even whether a directors’ meeting ever happened. What she did recall, as the opinion quotes it, was a more general statement: Zanetti wanted to open a biotech company and she would have a key role in it.
She also testified she lacked knowledge about intellectual property and was thinking Zanetti was taking care of that. She had not seen Transgenics’ entire business plan. She trusted him to protect her interest. She had no idea what it would cost to start a company and thought funds would come from outside investors rather than from her. She understood there would be profit for people involved, but she had no quantification, and she thought Zanetti would cover her interests. The court treated those admissions as going to the heart of her case, not as trivia.
The opinion notes that by the time of Zanetti’s renewed summary- judgment motion in 2010 she had not signed a new declaration under oath explaining the gap between the original declaration and the deposition, or claiming her memory had been restored. Without a recollection of a promise, the court said, she had no prospects for trial.
Documented · certainty
California contract law requires reasonably certain material terms. The appellate court held a jury could not reasonably find that element. The evidence, as recited, did not show a meeting of the minds on the material terms of any agreement, so breach and remedy were not capable of proof. That is a legal holding on this record. It is not a finding about Tehran.
Documented · constructive fraud
The complaint’s fraud claim, as the opinion describes it, was constructive fraud based on a fiduciary duty Zanetti supposedly owed Gerloni. Even if a fiduciary relationship were arguable — the court called that doubtful — the claim still rested on the same supposed promises. She did not raise a triable issue of material fact on those promises. Summary judgment for Zanetti was affirmed 1 February 2013.
Calendar fact · then the claim
Documented. The alleged Padtan share meeting is dated 14 January 2013. This opinion was filed 1 February 2013. That is eighteen calendar days. Two public dates. The dispute itself runs from a 1993 laboratory relationship through this 2013 affirmance. Zanetti’s antigenized- antibody and somatic-transgene-immunization work, and patents aimed at cytotoxic T-lymphocyte responses against tumor antigens including telomerase reverse transcriptase, are public science and public patent paper. A Cosmo securities note describes a later license fight. Gerloni’s move from accuser to CBI CEO in 2005 is recited on this same opinion.
Claimed. That the deposition “memory lapse” was contrived. That the family reached a deal with Zanetti to keep inventions tied up in court until after a 14 January 2013 transfer. That patents were then “released” on 3 February 2013 as a coordinated step. That this twenty-year docket was a shield for covert trials or for Iranome. Those readings are his. The opinion does not name Padtan Elm, Farideh, Ommid, or a Tehran share deed. A USPTO issue or assignment date of 3 February 2013 is not mounted here; do not flatten it into Thermo Fisher’s 3 February 2014 close of Life Technologies.
Investigator color — that a highly trained scientist forgetting promises a month after a declaration “borders on the absurd” — is argument about credibility. The court already treated the deposition as fatal to her remaining counts. That is enough for this page. It is not a finding she was a cut-out for Iranian work.
Context · Moores
A laboratory page prints Maurizio Zanetti as Director of the Laboratory of Immunology at UCSD Moores Cancer Center. Pedal / Curebound copy already lists Moores among funded institutions. Moores’ own Pilot Grant Awardees directory opens with Curebound/Padres Pedal the Cause Grants. On that same directory, under Gleiberman Head and Neck Center Pilot Grant, 2021 Project 3 is “Study of antitumor B cell immunity in head and neck cancer patients,” Maurizio Zanetti, MD. The hosted Gleiberman PDF is that abstract; Curebound is not printed on the PDF. Fall 2022 Curebound Cure Prize Project 1 on the same page is an ovarian-cancer MRI study, not this title. Two programs, one directory. The Gleiberman award is not a Curebound grant.
UCSD Profiles lists him as principal investigator on NIH R01HD025787, “Engineered CD4-like antibodies in neonatal HIV infection,” 2 May 1990 to 30 April 1993. That is the title on the profile. It is not “Regulation of Immune Response by B Cell Antigen Receptor.”
In 2013 the three NCI-designated cancer centers in La Jolla — Moores, Salk, and Sanford-Burnham — formed the San Diego NCI Cancer Centers Council, or C3. Scott Lippman’s Union-Tribune column that May names Scripps Research as one of the neighboring institutes those centers collaborate with. Moores’ own collaborating-sites page repeats the same three C3 members, then lists Scripps Research next door. Scripps Research is not a C3 member on that paper. There is still no joint document that lists Zanetti and Ommid Asbaghi. Fundraising geography is not a personnel page, and it is not a hip protocol.